Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
CORT Corcept Therapeutics Incorporated daily Stock Chart
CORT [NASD]
Corcept Therapeutics Incorporated
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E91.45 EPS (ttm)0.20 Insider Own9.66% Shs Outstand118.21M Perf Week-2.14%
Market Cap2.16B Forward P/E26.13 EPS next Y0.70 Insider Trans-0.21% Shs Float102.45M Perf Month-0.76%
Income24.20M PEG1.25 EPS next Q0.13 Inst Own64.40% Short Float7.02% Perf Quarter42.00%
Sales108.70M P/S19.89 EPS this Y216.90% Inst Trans1.04% Short Ratio4.99 Perf Half Y81.45%
Book/sh0.58 P/B31.53 EPS next Y65.09% ROA33.00% Target Price15.40 Perf Year185.78%
Cash/sh0.56 P/C32.71 EPS next 5Y73.20% ROE51.40% 52W Range6.11 - 20.77 Perf YTD151.93%
Dividend- P/FCF56.75 EPS past 5Y16.90% ROI18.10% 52W High-11.94% Beta2.06
Dividend %- Quick Ratio3.80 Sales past 5Y- Gross Margin97.60% 52W Low199.35% ATR1.00
Employees103 Current Ratio4.00 Sales Q/Q80.70% Oper. Margin23.60% RSI (14)49.30 Volatility5.88% 5.45%
OptionableYes Debt/Eq0.07 EPS Q/Q1194.50% Profit Margin22.30% Rel Volume1.04 Prev Close18.87
ShortableYes LT Debt/Eq0.00 EarningsOct 31 AMC Payout0.00% Avg Volume1.44M Price18.29
Recom2.60 SMA20-3.98% SMA507.24% SMA20053.06% Volume1,498,413 Change-3.07%
Aug-31-17Initiated Stifel Buy $20
Feb-02-17Initiated Ladenburg Thalmann Buy $14
Apr-21-15Initiated FBR Capital Outperform $12
Jan-13-14Downgrade Stifel Buy → Hold
Aug-09-13Downgrade Ladenburg Thalmann Buy → Neutral $3.30
Aug-09-13Downgrade Janney Buy → Neutral
Feb-21-12Reiterated JMP Securities Mkt Outperform $9 → $11
Jan-06-10Upgrade Ladenburg Thalmann Neutral → Buy $4
Jul-17-08Initiated Rodman & Renshaw Mkt Outperform $8
Jun-21-07Upgrade Punk, Ziegel & Co Mkt Perform → Accumulate
Oct-16-17 08:20AM  Today's Research Reports on Trending Tickers: Corcept Therapeutics and Orexigen Therapeutics ACCESSWIRE +5.30%
Oct-10-17 04:01PM  Weakness In Corcept Shares Is 'Overdone,' According To Analyst Benzinga -5.94%
01:39PM  Can Corcept Therapeutics Incorporateds (CORT) ROE Continue To Surpass The Industry Average? Simply Wall St.
Oct-09-17 11:24AM  ETFs with exposure to Corcept Therapeutics, Inc. : October 9, 2017 Capital Cube
Oct-06-17 09:03AM  Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Capital Cube
Sep-27-17 03:00AM  Stocks Showing Market Leadership: Sarepta Therapeutics Earns 91 RS Rating Investor's Business Daily
03:00AM  Stocks Flashing Renewed Technical Strength: Innoviva Investor's Business Daily
03:00AM  Acceleron Pharma Reaches 80-Plus Relative Strength Rating Benchmark Investor's Business Daily
Sep-26-17 07:38AM  Is It Too Late To Buy Corcept Therapeutics Incorporated (CORT)? Simply Wall St.
07:17AM  3 Bargain Biotech Stocks You Can Buy Today Motley Fool
03:00AM  Acorda Therapeutics Getting Closer To Key Technical Measure Investor's Business Daily
Sep-25-17 07:04AM  3 Highest-Growth Stocks in the Market Today Motley Fool +5.11%
Sep-14-17 05:39PM  4 Biotech Stocks That Show Promise on Sustainable Growth Zacks
11:11AM  3 Stocks That Have Doubled This Year Motley Fool
Aug-30-17 12:00PM  Harry Boxers four biotech stocks to watch MarketWatch
09:17AM  Pfizer's sNDA for Bosulif Accepted in the U.S. and Europe Zacks
Aug-29-17 10:36AM  Top Ranked Momentum Stocks to Buy for August 29th Zacks
Aug-28-17 07:04PM  Cramer's lightning round: I know I'm alone here, but I st... CNBC Videos
06:48PM  Cramer's lightning round: I know I'm alone here, but I still like the airlines CNBC
Aug-25-17 11:09AM  Mylan and Otsuka Ink Agreement to Commercialize Deltyba Zacks
10:45AM  Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars Zacks
Aug-24-17 11:55AM  BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End Zacks
10:57AM  Lannett (LCI) Q4 Earnings In Line, Stock Up on Solid View Zacks
10:35AM  4 of the Highest-Growth Stocks in Biotech Today Motley Fool
Aug-18-17 08:00AM  Today's Research Reports on Trending Tickers: Corcept Therapeutics Inc. and Opko Health Inc. ACCESSWIRE
Aug-16-17 01:43PM  Three Breakouts, And One Possible Breakdown In Cummins Forbes
12:58PM  Three Stocks Breaking Out Benzinga
11:40AM  Signet Jewelers could fall further, and 3 more stocks to watch MarketWatch
Aug-14-17 08:33AM  Why Corcept Therapeutics (CORT) Could Be Positioned for a Surge Zacks
Aug-12-17 07:50PM  Edited Transcript of CORT earnings conference call or presentation 1-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-09-17 06:05AM  Can The Uptrend Continue for Corcept Therapeutics (CORT)? Zacks
Aug-07-17 09:15AM  Top Ranked Momentum Stocks to Buy for August 7th Zacks +5.16%
Aug-03-17 01:27PM  These two biotech stocks are breaking out MarketWatch +6.13%
08:15AM  Corcept (CORT) Looks Good: Stock Moves Up 8.8% in Session Zacks
Aug-02-17 06:21PM  Why Corcept Therapeutics Incorporated Stock Surged Higher Today Motley Fool +8.78%
04:21PM  How These 2 Biotechs Defied The Downtrend To Hit Fresh Highs Investor's Business Daily
10:24AM  Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised Zacks
Aug-01-17 11:14PM  Corcept beats 2Q profit forecasts Associated Press
04:27PM  ETFs with exposure to Corcept Therapeutics, Inc. : August 1, 2017 Capital Cube
04:05PM  Corcept Therapeutics Announces Second Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update GlobeNewswire
Jul-26-17 08:08AM  3 Under-the-Radar Stocks in the Healthcare Sector Motley Fool
Jul-25-17 04:05PM  Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call GlobeNewswire
Jul-16-17 06:42AM  Is It Too Late to Get In on This Millionaire-Maker Stock? Motley Fool
Jul-13-17 05:44PM  Corcept Therapeutics Focuses on Korlym's Label Expansion Zacks
Jul-12-17 02:23PM  ETFs with exposure to Corcept Therapeutics, Inc. : July 12, 2017 Capital Cube
Jul-03-17 09:50AM  Why is Corcept's Stock Up More Than 60% So Far This Year? Zacks
Jun-30-17 02:49PM  ETFs with exposure to Corcept Therapeutics, Inc. : June 30, 2017 Capital Cube
Jun-26-17 08:43AM  Corcept Therapeutics Incorporated in 3 Charts Motley Fool
Jun-19-17 03:06PM  ETFs with exposure to Corcept Therapeutics, Inc. : June 19, 2017 Capital Cube
Jun-16-17 12:11PM  Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Capital Cube
Jun-15-17 08:32AM  Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : June 15, 2017 Capital Cube
May-24-17 12:12PM  Pharma Stock With Triple-Digit Growth Forming Blotchy Base Investor's Business Daily
May-18-17 01:37PM  ETFs with exposure to Corcept Therapeutics, Inc. : May 18, 2017 Capital Cube +7.84%
May-12-17 08:15AM  Blog Coverage: Synthetic Biologics Wins Breakthrough Therapy Designation for its Clostridium Difficile Infection Candidate Accesswire
May-11-17 12:00AM  4 of the Cheapest Biotech Stocks in the World Motley Fool
May-10-17 08:17AM  Corcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US : May 10, 2017 Capital Cube
May-04-17 08:40AM  Edited Transcript of CORT earnings conference call or presentation 1-May-17 9:00pm GMT Thomson Reuters StreetEvents
08:30AM  Corcept Therapeutics Announces Presentations on Mifepristone for the Treatment of Patients with Hypercortisolism at the American Association of Clinical Endocrinologists 26th Annual Congress Marketwired
May-01-17 05:01PM  Corcept posts 1Q profit Associated Press
04:05PM  Corcept Therapeutics Announces First Quarter 2017 Financial Results, Raises 2017 Revenue Guidance and Provides Corporate Update Marketwired
11:10AM  Investor Network: Corcept Therapeutics Incorporated. to Host Earnings Call Accesswire
Apr-27-17 11:01AM  Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View Zacks
Apr-25-17 04:09PM  Corcept Therapeutics, Inc. Value Analysis (NASDAQ:CORT) : April 25, 2017 Capital Cube
Apr-24-17 04:05PM  Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Conference Call Marketwired
08:42AM  Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : April 24, 2017 Capital Cube
Apr-21-17 06:24PM  Here's Why Corecept Therapeutics Incorporated Had a Rough Day Motley Fool -8.81%
Apr-20-17 10:30AM  Nivalis' (NVLS) Shares Down After Merger Deal with Alpine Zacks
Apr-06-17 07:00AM  Corcept (CORT) Up 18% Since Earnings Report: Can It Continue? Zacks
Mar-30-17 11:03AM  No. 5-Ranked Biotech Bolts Higher On Drug Results
Mar-29-17 04:51PM  Corcept (CORT) Strives to Commercialize Key Drug Korlym Zacks
Mar-20-17 03:03PM  Corcept Therapeutices Eyes Another Double TheStreet.com
Mar-17-17 09:30AM  Today's Research Reports on Stocks to Watch: Array Biopharma and Corcept Therapeutics Accesswire
Mar-10-17 04:39PM  Under-The-Radar Biotech Tests Buy Zone; Cancer Trial Results 'Encouraging' Investor's Business Daily +9.25%
01:04PM  CORCEPT THERAPEUTICS INC Financials
Mar-07-17 12:15PM  Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Capital Cube
Mar-06-17 08:44AM  Corcept beats 4Q profit forecasts Associated Press
08:37AM  CORCEPT THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure
08:30AM  Corcept Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results; Increases 2017 Revenue Guidance Marketwired
Feb-14-17 01:56PM  Corcept Therapeutics, Inc. Value Analysis (NASDAQ:CORT) : February 14, 2017 Capital Cube
Feb-13-17 04:19PM  CORCEPT THERAPEUTICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financi
Feb-02-17 07:23AM  Coverage initiated on Corcept Therapeutics by Ladenburg Thalmann
Jan-31-17 02:14AM  Edited Transcript of CORT earnings conference call or presentation 30-Jan-17 10:00pm GMT Thomson Reuters StreetEvents
Jan-30-17 04:05PM  Corcept Therapeutics Announces Preliminary Fourth Quarter and Full-Year 2016 Financial Results and Corporate Update; Provides 2017 Revenue Guidance Marketwired
07:07AM  Preliminary Q4 2016 Corcept Therapeutics Inc Earnings Release - After Market Close
Jan-23-17 04:05PM  Corcept Therapeutics to Announce Preliminary 2016 Financial Results, Provide 2017 Revenue Guidance and Corporate Update, and Host Conference Call Marketwired
Jan-11-17 07:26AM  Corcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US : January 11, 2017
Jan-09-17 07:25AM  3 Stocks Expected to More Than Double Their Earnings in 2017 at Motley Fool
Dec-23-16 09:23AM  Corcept Therapeutics, Inc. Value Analysis (NASDAQ:CORT) : December 23, 2016
Dec-22-16 07:26AM  Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : December 22, 2016
Dec-12-16 09:54AM  Corcept Korlym Positive in Phase I/II Breast Cancer Study
Dec-10-16 09:37PM  Should You Add Corcept Therapeutics Incorporated (CORT) To Your Portfolio? at Insider Monkey
08:30AM  Corcept Therapeutics Announces Encouraging Results of Phase 1/2 Trial of Mifepristone Plus Eribulin in Triple-Negative Breast Cancer Marketwired
Nov-11-16 08:35AM  Corcept (CORT) Looks Good: Stock Jumps 6.5% in Session +9.71%
Nov-02-16 08:12AM  Corcept (CORT) Beats on Q3 Earnings, Lifts Sales Guidance +8.53%
06:08AM  CORCEPT THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report
05:02AM  Edited Transcript of CORT earnings conference call or presentation 1-Nov-16 9:00pm GMT
Nov-01-16 05:40PM  Corcept beats 3Q profit forecasts
04:11PM  CORCEPT THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure
04:05PM  Corcept Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update Marketwired
07:07AM  Q3 2016 Corcept Therapeutics Inc Earnings Release - After Market Close
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer. In addition, it develops CORT125134 for the treatment of patients with Cushing's syndrome and solid-tumor cancers; and CLIA-validated assay to measure expression of the gene FKBP5, which is stimulated by cortisol activity at glucocorticoid receptor. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MAHONEY DAVID LDirectorJul 19Option Exercise2.2316,91537,7201,152,588Jul 20 09:09 PM
MAHONEY DAVID LDirectorJul 19Sale12.5016,915211,4581,135,673Jul 20 09:09 PM
MAHONEY DAVID LDirectorJul 18Option Exercise2.236,09113,5831,141,764Jul 20 09:09 PM
MAHONEY DAVID LDirectorJul 18Sale12.506,09176,1391,135,673Jul 20 09:09 PM
MAHONEY DAVID LDirectorJul 13Sale12.554846,0731,128,679Jul 14 05:35 PM
MAHONEY DAVID LDirectorJul 12Sale12.506,51081,3751,129,163Jul 14 05:35 PM
Robb Gary CharlesChief Financial OfficerMay 04Buy9.755,60054,5886,858May 08 05:14 PM
ENRIGHT PATRICK GDirectorMar 16Sale9.94269,9552,683,237114,675Mar 20 04:36 PM
ENRIGHT PATRICK GDirectorMar 15Sale10.24279,0202,856,766139,630Mar 15 06:45 PM
ENRIGHT PATRICK GDirectorMar 14Sale10.01300,0003,002,670145,113Mar 15 06:45 PM
ENRIGHT PATRICK GDirectorMar 13Sale11.1320,980233,491151,008Mar 15 06:45 PM
ENRIGHT PATRICK GDirectorMar 08Sale9.75750,0007,312,500151,420Mar 10 04:22 PM
ENRIGHT PATRICK GDirectorFeb 27Sale9.051,000,0009,050,000166,157Feb 27 07:04 PM
ENRIGHT PATRICK GDirectorFeb 23Sale8.651,500,00012,975,000185,807Feb 27 07:04 PM
Longitude Venture Partners L.P10% OwnerNov 25Sale9.392902,722180,103Nov 25 09:08 PM
Longitude Venture Partners L.P10% OwnerNov 25Sale9.3914,451135,65013,775,899Nov 25 09:08 PM
ENRIGHT PATRICK GDirectorNov 25Sale9.3914,741138,372180,103Nov 25 09:05 PM
ENRIGHT PATRICK GDirectorNov 23Sale9.3012,600117,228180,393Nov 25 09:05 PM
Longitude Venture Partners L.P10% OwnerNov 23Sale9.302482,307180,393Nov 25 09:08 PM
Longitude Venture Partners L.P10% OwnerNov 23Sale9.3012,352114,92113,790,350Nov 25 09:08 PM
Longitude Venture Partners L.P10% OwnerNov 22Sale9.331891,763180,641Nov 25 09:08 PM
Longitude Venture Partners L.P10% OwnerNov 22Sale9.339,41187,80213,802,702Nov 25 09:08 PM
ENRIGHT PATRICK GDirectorNov 22Sale9.339,60089,565180,641Nov 25 09:05 PM
ENRIGHT PATRICK GDirectorNov 21Sale9.39118,3851,111,162180,830Nov 21 09:02 PM
Longitude Venture Partners L.P10% OwnerNov 21Sale9.392,32721,841180,830Nov 21 09:10 PM
Longitude Venture Partners L.P10% OwnerNov 21Sale9.39116,0581,089,32013,812,113Nov 21 09:10 PM
Longitude Venture Partners L.P10% OwnerNov 18Sale9.471,97618,720183,157Nov 21 09:10 PM
Longitude Venture Partners L.P10% OwnerNov 18Sale9.4798,586933,96413,928,171Nov 21 09:10 PM
ENRIGHT PATRICK GDirectorNov 18Sale9.47100,562952,684183,157Nov 21 09:02 PM
ENRIGHT PATRICK GDirectorNov 17Sale9.64325,1533,135,580185,133Nov 21 09:02 PM
Longitude Venture Partners L.P10% OwnerNov 17Sale9.64318,7643,073,96914,026,757Nov 21 09:10 PM
ENRIGHT PATRICK GDirectorNov 16Sale9.5117,394165,394191,522Nov 17 04:36 PM
ENRIGHT PATRICK GDirectorNov 15Sale9.55157,4531,504,211191,864Nov 17 04:36 PM
BELANOFF JOSEPH KCHIEF EXECUTIVE OFFICERNov 11Option Exercise1.50200,000300,0002,364,195Nov 14 07:43 PM
MAHONEY DAVID LDirectorNov 11Option Exercise2.7030,00081,0001,199,320Nov 14 08:02 PM
WILSON JAMES NDirectorNov 11Option Exercise1.5114,21621,466915,283Nov 14 07:40 PM
WILSON JAMES NDirectorNov 11Sale9.1014,216129,387901,067Nov 14 07:40 PM
BELANOFF JOSEPH KCHIEF EXECUTIVE OFFICERNov 11Sale9.10200,0001,820,3002,164,195Nov 14 07:43 PM
MAHONEY DAVID LDirectorNov 11Sale9.3530,000280,5001,169,320Nov 14 08:02 PM
BELANOFF JOSEPH KCHIEF EXECUTIVE OFFICERNov 10Option Exercise1.50300,000450,0002,464,195Nov 14 07:43 PM
WILSON JAMES NDirectorNov 10Option Exercise1.5133,24750,203934,314Nov 14 07:40 PM
BELANOFF JOSEPH KCHIEF EXECUTIVE OFFICERNov 10Sale8.90300,0002,670,4502,164,195Nov 14 07:43 PM
WILSON JAMES NDirectorNov 10Sale8.9033,247295,948901,067Nov 14 07:40 PM
WILSON JAMES NDirectorNov 09Option Exercise1.51111,349168,1371,012,416Nov 14 07:40 PM
WILSON JAMES NDirectorNov 09Sale8.32111,349926,914901,067Nov 14 07:40 PM
BELANOFF JOSEPH KCHIEF EXECUTIVE OFFICERNov 07Option Exercise1.50500,000750,0002,570,662Nov 09 08:29 PM
BELANOFF JOSEPH KCHIEF EXECUTIVE OFFICERNov 07Sale8.31500,0004,152,5472,164,195Nov 09 08:29 PM
open in yahoo | open in reuters | open in google